文献速递泌尿生殖与妇科肿瘤放疗

准确预测挽救性放疗后生化失败的长期风险,包括盆腔淋巴结照射的影响

Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation.
PubMed 文献 · Radiother Oncol · 2022-08-04

研究基于795例前列腺切除术后接受挽救性放疗(SRT)的患者数据,建立并验证了一个可解释的泊松方程模型,用于预测生化失败(BF)风险,并纳入盆腔淋巴结照射(PNI)的影响。模型在验证组中表现良好(斜率=0.89,R²=0.85),结果提示最佳SRT剂量为70-74 Gy,PNI可降低高危患者BF风险。

要点

  • 基于795例患者的可解释方程可预测SRT后长期BF风险,并在验证组中验证(斜率=0.89,R²=0.85)。
  • 模型纳入SRT前PSA、放射敏感性α、克隆源密度C、处方的EQD2及PNI恢复因子λ。
  • 结果提示最佳SRT剂量为70-74 Gy,PNI对高危患者BF的降低幅度更大。

核心结论

  • 可解释的通用方程能满意地预测SRT后BF的长期风险,模型经过独立验证,并提供了计算工具。

研究设计与样本

  • 回顾性分析795例pT2-pT3、pN0/pN1/pNx(n=627/94/74)患者,随访≥5年且放疗前PSA≤2 ng/mL,随机分为训练组(n=528)和验证组(n=267),训练组数据用最小二乘法拟合。

主要发现

  • 中位随访8.5年,中位SRT前PSA为0.43 ng/mL,中位EQD2为71.3 Gy,331/795例接受了PNI。
  • 最具临床意义的预后分组为pT3b和/或ISUP4-5对比pT2/3a和ISUP1-3。
  • 低危/高危组最佳拟合参数分别为αeff=0.26/0.23 Gy⁻¹、C=10⁷/10⁷、B=0.40/0.97、λ=0.87/0.41。
  • 验证组性能确认(斜率=0.89,R²=0.85)。
  • 结果提示最佳SRT剂量为70-74 Gy;在这些剂量下,PNI对SRT后BF的估计降低幅度:低危患者PSA>1 ng/mL时>5%,高危患者PSA>0.15 ng/mL时>5%,高危患者SRT前PSA>0.25 ng/mL时>10%。

关键数值与推荐

  • 模型方程包含SRT前PSA、放射敏感性α、克隆源密度C、处方的EQD2(α/β=1.5 Gy)及因子(1-BxλxPSA),λ为PNI恢复。
  • 低危组最佳拟合参数:αeff=0.26 Gy⁻¹,C=10⁷,B=0.40,λ=0.87;高危组:αeff=0.23 Gy⁻¹,C=10⁷,B=0.97,λ=0.41。
  • 验证组校准斜率=0.89,R²=0.85。
  • 结果提示最佳SRT剂量为70-74 Gy。
  • PNI估计降低BF幅度:低危患者PSA>1 ng/mL时>5%,高危患者PSA>0.15 ng/mL时>5%,高危患者SRT前PSA>0.25 ng/mL时>10%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Explainable models of long-term risk of biochemical failure (BF) after post-prostatectomy salvage radiotherapy (SRT) are lacking. A previously introduced radiobiology-based formula was adapted to incorporate the impact of pelvic nodes irradiation (PNI). MATERIALS AND METHODS: The risk of post-SRT BF may be expressed by a Poisson-based equation including pre-SRT PSA, the radiosensitivity α, the clonogen density C, the prescribed dose (in terms of EQD2, α/β = 1.5 Gy) and a factor (1-BxλxPSA) accounting for clonogens outside the irradiated volume, being λ the recovery due to PNI. Data of 795 pT2-pT3, pN0/pN1/pNx (n = 627/94/74) patients with follow-up ≥ 5 years and pre-RT PSA ≤ 2 ng/mL were randomly split into training (n = 528) and validation (n = 267) cohorts; the training cohort data were fitted by the least square method. Separate fits were performed for different risk groups. Model performances were assessed by calibration plots and tested in the validation group. RESULTS: The median follow-up was 8.5y, median pre-SRT PSA and EQD2 were 0.43 ng/mL and 71.3 Gy respectively; 331/795 pts received PNI. The most clinically significant prognostic grouping was pT3b and/or ISUP4-5 versus pT2/3a and ISUP1-3. Best-fit parameters were αeff = 0.26/0.23 Gy-1, C = 107/107, B = 0.40/0.97, λ = 0.87/0.41 for low/high-risk group. Performances were confirmed in the validation group (slope = 0.89,R2 = 0.85). Results suggested optimal SRT dose at 70-74 Gy. The estimated reduction of post-SRT BF due to PNI at these dose values was > 5 % for PSA > 1/>0.15 ng/mL for low/high-risk patients, being > 10 % for high-risk patients with pre-SRT PSA > 0.25 ng/mL. CONCLUSION: An explainable one-size-fits-all equation satisfactorily predicts long-term risk of post-SRT BF. The model was independently validated. A calculator tool was made available.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cozzarini C, Olivieri M, Magli A, et al. Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation. Radiother Oncol. 2022. PMID: 35934169. doi:10.1016/j.radonc.2022.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。